Defining the impact of adjuvant therapy in molecularly defined subsets of gastrointestinal stromal tumor : From lumping to splitting
Menée à partir de données portant sur 341 patients atteints d'une tumeur stromale gastro-intestinale inclus dans un essai clinique évaluant l'efficacité de l'imatinib en traitement adjuvant (âge médian lors de l'inclusion dans l'essai : 62 ans), cette étude évalue les effets de mutations des gènes
In 1998, the modern era of recognizing gastrointestinal stromal tumor (GIST) as a unique entity began, with a report linking KIT protein expression and gene mutations to the putative cell of origin for GIST.1 Immunohistochemical detection of the KIT protein provided a tool to distinguish GIST from other types of cancer (particularly leiomyosarcoma). With accurate diagnosis, it became clear that while some cases of metastatic leiomyosarcoma responded to chemotherapy, the response rate of GIST was essentially 0%.2 Therefore, KIT expression could be used to identify patients with GIST who would not benefit from conventional chemotherapy.
JAMA Oncology , éditorial en libre accès, 2016